{"nctId":"NCT04382924","briefTitle":"Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease","startDateStruct":{"date":"2020-08-05","type":"ACTUAL"},"conditions":["COVID"],"count":168,"armGroups":[{"label":"Treatment Arm A","type":"EXPERIMENTAL","interventionNames":["Drug: NP-120 (Ifenprodil)"]},{"label":"Control Arm","type":"NO_INTERVENTION","interventionNames":[]},{"label":"Treatment Arm B","type":"EXPERIMENTAL","interventionNames":["Drug: NP-120 (Ifenprodil)"]}],"interventions":[{"name":"NP-120 (Ifenprodil)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male and female subjects aged ≥18 years of age\n2. Confirmed coronavirus infection\n\n   1. Positive real-time fluorescence polymerase chain reaction of the patient's respiratory or blood specimens for COVID-19 nucleic acid\n   2. Viral gene sequences in respiratory or blood specimens that are highly homologous to COVID-19\n   3. Any other diagnostic test accepted by local regulatory authorities\n3. Must be hospitalized and requiring supplemental oxygen, or on non-invasive ventilation or high flow oxygen devices (Score of 4 or 5 on WHO Ordinal Clinical Scale)\n4. Female subjects of childbearing potential who are sexually active with a non-sterilized male partner must use at least 1 highly effective method of contraception (e.g. oral contraceptives, intrauterine device, diaphragm plus spermicide) from the time of screening and must agree to continue using such precautions for 90 days after the final dose of study drug(s)\n5. Non-sterilized males who are sexually active with a female partner of childbearing potential must use condom plus spermicide from day 1 through 90 days after receipt of the last dose of study drug(s)\n6. Subjects (or reasonable legal designate) must have the capacity to understand, sign and date a written, informed consent form and any required authorization prior to initiation of any study procedures\n\nExclusion Criteria:\n\n1. Patients with vasodilatory shock, orthostatic hypotension, hypotension, or tachycardia at screening/baseline\n2. Patients experiencing cerebral hemorrhage or cerebral infarction at baseline\n3. ALT/AST \\> 5 times the upper limit of normal; Child-Pugh Score 10 to 15\n4. Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR \\< 30)\n5. Patients on mechanical ventilation or extracorporeal membrane oxygenation (ECMO)\n6. Patients taking droxidopa\n7. Pregnant and lactating women and those planning to get pregnant\n8. Known or suspected allergy to the trial drug or the relevant drugs given in the trial\n9. Presence of other disease that may interfere with testing procedures or in the judgement of the Investigator may interfere with trial participation or may put the patient at risk when participating in this trial\n10. Know inability of patient to comply with the protocol for the duration of the study\n11. Involvement in a clinical research study within 4 weeks prior to screening and/or prior enrollment in the study or plan to participate in another interventional clinical trial during the study period. Participation in observational registry studies is permitted.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Patient Clinical Status (on the WHO 7-point Ordinal Scale) at Day 15 in IP Versus SOC Control Group Patients:","description":"1. Not hospitalized, no limitations on activities\n2. Not hospitalized, limitation on activities\n3. Hospitalized, not requiring supplemental oxygen\n4. Hospitalized, requiring supplemental oxygen\n5. Hospitalized, on non-invasive ventilation or high flow oxygen devices\n6. Hospitalized, on invasive mechanical ventilation or ECMO\n7. Death","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Status on an Ordinal Scale Assessed Daily While Hospitalized and on Days 15 and 28 in IP Versus Control Group Patients","description":"WHO status of subjects at timepoints from baseline to day 28\n\n1. Not hospitalized, no limitations on activities\n2. Not hospitalized, limitation on activities\n3. Hospitalized, not requiring supplemental oxygen\n4. Hospitalized, requiring supplemental oxygen\n5. Hospitalized, on non-invasive ventilation or high flow oxygen devices\n6. Hospitalized, on invasive mechanical ventilation or ECMO\n7. Death","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.23","spread":"0.425"},{"groupId":"OG001","value":"4.25","spread":"0.548"},{"groupId":"OG002","value":"4.25","spread":"0.427"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.22","spread":"0.503"},{"groupId":"OG001","value":"4.22","spread":"0.718"},{"groupId":"OG002","value":"4.29","spread":"0.7063"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.12","spread":"0.627"},{"groupId":"OG001","value":"4.14","spread":"0.917"},{"groupId":"OG002","value":"4.18","spread":"0.819"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.89","spread":"0.767"},{"groupId":"OG001","value":"4.02","spread":"1.012"},{"groupId":"OG002","value":"4.04","spread":"0.988"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.87","spread":"0.777"},{"groupId":"OG001","value":"4.09","spread":"1.156"},{"groupId":"OG002","value":"3.97","spread":"1.098"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.87","spread":"1.343"},{"groupId":"OG001","value":"2.95","spread":"1.628"},{"groupId":"OG002","value":"2.96","spread":"1.665"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.59","spread":"1.384"},{"groupId":"OG001","value":"1.80","spread":"1.608"},{"groupId":"OG002","value":"1.73","spread":"1.730"}]}]}]},{"type":"SECONDARY","title":"NEWS Assessed Days 3, 5, 8 ,11 Daily While Hospitalized and on Days 15 and 29 in IP Versus Control Group Patients","description":"National Early Warning Score assessed between baseline and Day 29 on subjects in 20, 40 mg TID NP-120 arms versus control group\n\nThe National Early Warning Score (NEWS) scale is a composite of 7 physiological parameters: Respiration Rate (per minute),Oxygen Saturations (%), Any Supplemental Oxygen, Temperature (°C), Systolic BP (mmHg), Heart Rate (per minute), Level of Consciousness. The aggregate results from all 7 physiological parameters are used to obtain the NEW Score., ranging from 0 - 20. Higher values reflect a worse outcome.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"1.83"},{"groupId":"OG001","value":"4.5","spread":"1.58"},{"groupId":"OG002","value":"4.5","spread":"1.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"1.90"},{"groupId":"OG001","value":"3.7","spread":"1.60"},{"groupId":"OG002","value":"4.4","spread":"1.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"2.04"},{"groupId":"OG001","value":"3.3","spread":"1.95"},{"groupId":"OG002","value":"3.7","spread":"1.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"2.33"},{"groupId":"OG001","value":"3.1","spread":"2.04"},{"groupId":"OG002","value":"3.0","spread":"2.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"2.21"},{"groupId":"OG001","value":"3.0","spread":"2.60"},{"groupId":"OG002","value":"3.2","spread":"2.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"2.85"},{"groupId":"OG001","value":"1.8","spread":"2.38"},{"groupId":"OG002","value":"1.8","spread":"2.37"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.97"},{"groupId":"OG001","value":"1.4","spread":"2.10"},{"groupId":"OG002","value":"1.3","spread":"2.11"}]}]}]},{"type":"SECONDARY","title":"Rate of Mechanical Ventilation in IP Versus Control Group Patients","description":"Rate of mechanical ventilation in 20 and 40 mg TID NP-120 versus control group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Mechanical Ventilation (if Applicable) in IP Versus Control Group Patients","description":"Duration of mechanical ventilation in 20 and 40 mg TID subjects versus control who experience mechanical ventilation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Supplemental Oxygen in IP Versus Control Group Patients","description":"Duration in patients only receiving supplemental oxygen in IP versus control group up to Day 29","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"39","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Return to Room Pressure (SpO2 > 94%) on Room Air","description":"Time to return to room pressure (SpO2 \\> 94%) on room air in patients in 20, 40 mg TID NP-120 groups versus control group with 94% blood oxygen levels at enrolment\n\nTime-to-event endpoints with competing risk were analysed for each dosing group using the Cumulative Incidence Function-CIF (KM) graphical display. Data represents the time (in Days) it took for all participants in the group to return to room pressure air (e.g. the time when the CIF curve hit 100%).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration in ICU (if Applicable) in IP Versus Control Group Patients","description":"Duration of subject in ICU in 20 and 40 TID mg groups versus control group patients","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Mortality in IP Versus Control Group Patients","description":"Rate of Overall Mortality in 20, 40 mg TID groups versus control group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Hospitalization in IP Versus Control Group Patients","description":null,"classes":[]},{"type":"SECONDARY","title":"Time to Discharge in IP Versus Control Group Patients","description":null,"classes":[]},{"type":"SECONDARY","title":"Effect on the Rate of Change of Partial Pressure of Oxygen (PaO2) and PaO2/FiO2 Ratio Taken at Baseline and Measured Once Daily up to 2 Weeks of Treatment in IP Versus Control Group Patients","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":52},"commonTop":["Hepatocellular injury","Oral candidiasis","Hyperglycaemia","Hypoalbuminaemia","Constipation"]}}}